Tacrolimus

• 

  Subject Areas on Research

  • "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. 
  • A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation. 
  • A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. 
  • A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study. 
  • A non-canonical RNA degradation pathway suppresses RNAi-dependent epimutations in the human fungal pathogen Mucor circinelloides. 
  • A prospective randomized trial of FK506-based immunosuppression after renal transplantation. 
  • A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. 
  • A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. 
  • A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. 
  • A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. 
  • A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. 
  • A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. 
  • A systematic review of morphea treatments and therapeutic algorithm. 
  • Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and mycophenolate mofetil in a liver transplant patient: a case report and review of the literature. 
  • Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. 
  • Adenovirus infections in pediatric small bowel transplant recipients. 
  • Advances in pancreas transplantation: the University of Wisconsin experience. 
  • Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 
  • Adverse effects of FK 506 overdosage after liver transplantation. 
  • Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 
  • An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. 
  • An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. 
  • Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. 
  • Antifungal drug resistance evoked via RNAi-dependent epimutations. 
  • Antifungal effects of cyclosporine and FK 506 are mediated via immunophilin-dependent calcineurin inhibition. 
  • Broad antifungal resistance mediated by RNAi-dependent epimutation in the basal human fungal pathogen Mucor circinelloides. 
  • Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. 
  • Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. 
  • Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. 
  • Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain. 
  • Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. 
  • Calcineurin is essential for survival during membrane stress in Candida albicans. 
  • Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains. 
  • Calcineurin is required for hyphal elongation during mating and haploid fruiting in Cryptococcus neoformans. 
  • Calcineurin is required for virulence of Cryptococcus neoformans. 
  • Calcineurin mediates pancreatic growth in protease inhibitor-treated mice. 
  • Calcineurin orchestrates dimorphic transitions, antifungal drug responses and host-pathogen interactions of the pathogenic mucoralean fungus Mucor circinelloides. 
  • Calcineurin plays key roles in the dimorphic transition and virulence of the human pathogenic zygomycete Mucor circinelloides. 
  • Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK506 in Cryptococcus neoformans. 
  • Calcineurin. Structure, function, and inhibition. 
  • Calcium- and calcineurin-independent roles for calmodulin in Cryptococcus neoformans morphogenesis and high-temperature growth. 
  • Campath-1H in intestinal and multivisceral transplantation: preliminary data. 
  • Cell biology. A fungal Achilles' heel. 
  • Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. 
  • Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. 
  • Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus. 
  • Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. 
  • Clinical intestinal transplantation: new perspectives and immunologic considerations. 
  • Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. 
  • Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. 
  • Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. 
  • Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. 
  • Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. 
  • Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. 
  • Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 
  • Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. 
  • Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. 
  • Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. 
  • Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 
  • Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. 
  • Cryptococcus neoformans methionine synthase: expression analysis and requirement for virulence. 
  • Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. 
  • Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. 
  • Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 
  • Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 
  • Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. 
  • Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. 
  • Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 
  • Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 
  • Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 
  • Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. 
  • Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. 
  • Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 
  • Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events. 
  • Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. 
  • FK 506 induction and rescue therapy in pancreas transplant recipients. 
  • FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 
  • FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. 
  • FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. 
  • FK506 in pediatric kidney transplantation--primary and rescue experience. 
  • FKBP12 controls aspartate pathway flux in Saccharomyces cerevisiae to prevent toxic intermediate accumulation. 
  • FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes. 
  • FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. 
  • FKBP12 physically and functionally interacts with aspartokinase in Saccharomyces cerevisiae. 
  • FKBP12-Dependent Inhibition of Calcineurin Mediates Immunosuppressive Antifungal Drug Action in Malassezia. 
  • Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. 
  • Gq signaling causes glomerular injury by activating TRPC6. 
  • Guidance for liver transplant immunosuppression. 
  • Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents. 
  • Heat shock protein 90 is required for conidiation and cell wall integrity in Aspergillus fumigatus. 
  • Hmo1p, a high mobility group 1/2 homolog, genetically and physically interacts with the yeast FKBP12 prolyl isomerase. 
  • Human immunodeficiency virus. Chaperoning a pathogen. 
  • Idiopathic intracranial hypertension following kidney transplantation: a case report and review of the literature. 
  • Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. 
  • Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. 
  • Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 
  • Immunosuppressive protocols and immunological challenges related to hand transplantation. 
  • Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. 
  • Improving results of pediatric renal transplantation. 
  • In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates. 
  • In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 
  • Incidence of CD4+ IL-2R alpha+ and CD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (3 months) FK 506 therapy. 
  • Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 
  • Infectious complications after small bowel transplantation in adults. 
  • Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. 
  • Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. 
  • Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. 
  • Laryngeal transplantation in the setting of cancer: a rat model. 
  • Late graft loss and long-term outcome after isolated intestinal transplantation in children. 
  • Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. 
  • Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 
  • Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 
  • Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. 
  • Myristoylation of calcineurin B is not required for function or interaction with immunophilin-immunosuppressant complexes in the yeast Saccharomyces cerevisiae. 
  • Nerve activity-dependent modulation of calcineurin signaling in adult fast and slow skeletal muscle fibers. 
  • Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 
  • Novel motif in calcineurin catalytic subunit is required for septal localization of calcineurin in Aspergillus fumigatus. 
  • Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 
  • Obesity following kidney transplantation and steroid avoidance immunosuppression. 
  • One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. 
  • Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. 
  • Outcome of kidney transplantation in African-Americans using tacrolimus. 
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. 
  • Pediatric kidney transplantation at the University of Pittsburgh. 
  • Pediatric renal transplantation under tacrolimus-based immunosuppression. 
  • Peripheral blood detection of systemic graft-specific xeno-antibodies following transplantation of human neural progenitor cells into the porcine spinal cord. 
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 
  • Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. 
  • Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. 
  • Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. 
  • Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. 
  • Potentiation of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506. 
  • Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 
  • Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. 
  • Preliminary experience with FK 506 in pancreas transplant recipients. 
  • Prolyl isomerases in yeast. 
  • Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. 
  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. 
  • Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. 
  • Pseudo-Pelger-Huët anomaly induced by transplant medications. 
  • Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. 
  • R73A and H144Q mutants of the yeast mitochondrial cyclophilin Cpr3 exhibit a low prolyl isomerase activity in both peptide and protein-folding assays. 
  • Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. 
  • Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells. 
  • Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. 
  • Recent advances in hepatic transplantation at the University of Pittsburgh. 
  • Regulation of tumor necrosis factor cytotoxicity by calcineurin. 
  • Renal transplantation under FK 506 in African-Americans: early experience. 
  • Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. 
  • Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. 
  • Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. 
  • Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. 
  • Signal-transduction cascades as targets for therapeutic intervention by natural products. 
  • Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. 
  • Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. 
  • Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. 
  • Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 
  • Surfactant protein D binding to Aspergillus fumigatus hyphae is calcineurin-sensitive. 
  • Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. 
  • Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. 
  • System for integrated adherence monitoring: real-time non-adherence risk assessment in pediatric kidney transplantation. 
  • T cell activation up-regulates the expression of the focal adhesion kinase Pyk2: opposing roles for the activation of protein kinase C and the increase in intracellular Ca2+. 
  • Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. 
  • Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. 
  • Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. 
  • Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. 
  • Tacrolimus and sirolimus: when bad things happen to good drugs. 
  • Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. 
  • Tacrolimus in pediatric renal transplantation. 
  • Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. 
  • Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. 
  • Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. 
  • Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. 
  • Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. 
  • Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. 
  • Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. 
  • Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. 
  • Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: implications for cytokine receptor signaling. 
  • The C2 domain protein Cts1 functions in the calcineurin signaling circuit during high-temperature stress responses in Cryptococcus neoformans. 
  • The RAM1 gene encoding a protein-farnesyltransferase beta-subunit homologue is essential in Cryptococcus neoformans. 
  • The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 
  • The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. 
  • The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 
  • The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae. 
  • The importance of studying history: lessons learnt from a trial of tacrolimus in myasthenia gravis. 
  • The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. 
  • Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 
  • Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. 
  • Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. 
  • Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 
  • Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients. 
  • Update on new immunomodulatory agents. 
  • Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 
  • Weaning of immunosuppression in liver transplant recipients. 
  • vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. 
• 

  Keywords of People

  • Juvvadi, Praveen Rao, Assistant Professor in Pediatrics, Pediatrics, Infectious Diseases
  • Steinbach, William J., Samuel L. Katz Distinguished Professor of Pediatrics, Duke Innovation & Entrepreneurship